ConvaTec Group (LON:CTEC) Stock Price Up 0.1% – What’s Next?

ConvaTec Group PLC (LON:CTEC) rose 0.1% on Tuesday . The stock traded as high as GBX 231.40 and last traded at GBX 231.40. Approximately 5,842,938 shares traded hands during mid-day trading, a decline of 13% from the average daily volume of 6,749,058 shares. The stock had previously closed at GBX 231.20.

Analysts Set New Price Targets

Several research firms recently commented on CTEC. Peel Hunt reaffirmed an “add” rating and issued a GBX 270 price objective on shares of ConvaTec Group in a research report on Thursday, November 13th. UBS Group restated a “buy” rating and set a GBX 375 price objective on shares of ConvaTec Group in a report on Friday, November 7th. Finally, JPMorgan Chase & Co. reissued an “overweight” rating on shares of ConvaTec Group in a research report on Friday, November 14th. Six investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, ConvaTec Group presently has a consensus rating of “Buy” and a consensus price target of GBX 318.67.

ConvaTec Group Trading Up 0.1%

The company has a current ratio of 2.26, a quick ratio of 0.96 and a debt-to-equity ratio of 85.32. The company has a market cap of £4.51 billion, a PE ratio of 21.83, a price-to-earnings-growth ratio of 0.93 and a beta of 0.64. The firm has a fifty day moving average of GBX 236.80 and a two-hundred day moving average of GBX 238.07.

About ConvaTec Group

ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, and bladder cancer.